Evidence map›Paper›PMID 38901603›Full record

ArticleKidney international2024

Imaging kidney inflammation using an oxidatively activated MRI probe.

Ivy A Rosales, Iris Yuwen Zhou, Ilknur Ay, Mozhdeh Sojoodi, Meghan E Sise, Eric M Gale

Abstract read
In one paragraph

Article in Kidney international, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ivy A RosalesDepartment of Pathology, Immunopathology Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Iris Yuwen ZhouAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Ilknur AyAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA.
Mozhdeh SojoodiDivision of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Meghan E SiseDivision of Nephrology, Department of Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Eric M GaleAthinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts, USA. Electronic address: emgale@mgh.harvard.edu.

Funding

Molecular Magnetic Resonance Imaging of InflammationR01DK120663 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI Eric Michael Gale · 2019 to 2026
$4.0M
Quantitative MRI-PET Imaging of Pulmonary FibrosisK25HL148837 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI ZHOU, IRIS YUWEN · 2020 to 2023
$686k
Noninvasive Nephritis ImagingR21DK130004 · NIDDK · MASSACHUSETTS GENERAL HOSPITAL · PI GALE, ERIC MICHAEL · 2021 to 2022
$460k
NHLBI NIH HHS K25 HL148837NIDDK NIH HHS R01 DK120663NIDDK NIH HHS R21 DK130004
6 · The paper itself

Abstract

Imaging tools for kidney inflammation could improve care for patients suffering inflammatory kidney diseases by lessening reliance on percutaneous biopsy or biochemical tests alone. During kidney inflammation, infiltration of myeloid immune cells generates a kidney microenvironment that is oxidizing relative to normal kidney. Here, we evaluated whether magnetic resonance imaging (MRI) using the redox-active iron (Fe) complex Fe-PyC3A as an oxidatively activated probe could serve as a marker of kidney inflammation using mouse models of unilateral ischemia-reperfusion injury (IRI) and lupus nephritis (MRL-lpr mice). We imaged unilateral IRI in gp91phox knockout mice, which are deficient in the nicotinamide oxidase II (NOX2) enzyme required for myeloid oxidative burst, as loss of function control, and imaged MRL/MpJ mice as non-kidney involved lupus control. Gadoterate meglumine was used as a non-oxidatively activated control MRI probe. Fe-PyC3A safety was preliminarily examined following a single acute dose. Fe-PyC3A generated significantly greater MRI signal enhancement in the IRI kidney compared to the contralateral kidney in wild-type mice, but the effect was not observed in the NOX2-deficient control. Fe-PyC3A also generated significantly greater kidney enhancement in MRL-lpr mice compared to MRL/MpJ control. Gadoterate meglumine did not differentially enhance the IRI kidney over the contralateral kidney and did not differentially enhance the kidneys of MRL-lpr over MRL/MpJ mice. Fe-PyC3A was well tolerated at the highest dose evaluated, which was a 40-fold greater than required for imaging. Thus, our data indicate that MRI using Fe-PyC3A is specific to an oxidizing kidney environment shaped by activity of myeloid immune cells and support further evaluation of Fe-PyC3A for imaging kidney inflammation.

Indexed as

Disease Models, AnimalKidneyLupus NephritisMagnetic Resonance ImagingMice, KnockoutNADPH Oxidase 2Oxidation-ReductionReperfusion InjuryAnimalsContrast MediaFemaleMaleMembrane GlycoproteinsMiceMice, Inbred C57BLMice, Inbred MRL lprContrast MediaCybb protein, mouseMembrane GlycoproteinsNADPH Oxidase 2inflammationischemia reperfusionlupus nephritisMRI

Identifiers

PMID38901603
PMCPMC11416327

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.